- Report
- December 2023
- 80 Pages
India
From €1421EUR$1,500USD£1,200GBP
- Report
- December 2023
- 80 Pages
Germany
From €1421EUR$1,500USD£1,200GBP
- Report
- December 2023
- 80 Pages
France
From €1421EUR$1,500USD£1,200GBP
- Report
- December 2023
- 80 Pages
China
From €1421EUR$1,500USD£1,200GBP
- Report
- December 2023
- 80 Pages
Brazil
From €1421EUR$1,500USD£1,200GBP
- Report
- December 2023
- 80 Pages
Argentina
From €1421EUR$1,500USD£1,200GBP
- Report
- June 2023
- 27 Pages
Global
€11608EUR$12,250USD£9,797GBP
- Report
- January 2025
- 84 Pages
Global
From €3500EUR$3,957USD£3,057GBP
- Report
- October 2023
- 87 Pages
Global
From €3500EUR$3,957USD£3,057GBP
- Drug Pipelines
- June 2021
- 847 Pages
Global
From €2369EUR$2,500USD£1,999GBP
- Report
- December 2023
- 100 Pages
Africa
From €1895EUR$2,000USD£1,599GBP
- Report
- September 2022
- 293 Pages
Global
From €3383EUR$3,570USD£2,855GBP
The Eczema Drug market is a subset of the Dermatological Drugs market, which includes medications used to treat skin conditions. Eczema drugs are used to treat the symptoms of eczema, a chronic skin condition characterized by red, itchy, and inflamed skin. These drugs are typically topical creams, ointments, and lotions, and may contain corticosteroids, calcineurin inhibitors, and other active ingredients. In addition to treating the symptoms of eczema, these drugs may also help to reduce the risk of infection and improve the overall quality of life for those affected by the condition.
Some companies in the Eczema Drug market include GlaxoSmithKline, Pfizer, Novartis, Sanofi, and Mylan. Show Less Read more
